Macitentan, Catalog: B1856

Alternate Names N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'- propylsulfamide;  ACT-064992

Appearance Crystalline solid

CAS # 441798-33-0 

Molecular Formula C₁₉H₂₀Br₂N₆O₄S 

Molecular Weight 588.27

Purity ≥ 98% by HPLC

Solubility DMSO

SMILES CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br

InChi InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)

InChi Key JGCMEBMXRHSZKX-UHFFFAOYSA-N

PubChem CID 16004692

Storage Conditions -20°C

Shipping Conditions Gel Pack

Usage For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.

Macitentan is an orally active endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH). It specifically targets the endothelin receptors type A and type B (ETA and ETB receptors). Endothelin is a peptide that constricts blood vessels and promotes cell proliferation, and its dysregulation is associated with PAH, a condition characterized by high blood pressure in the arteries of the lungs.